Viking Therapeutics Newsroom

Positive Phase 2 Trial Results Drive Viking Therapeutics (VKTX) Stock Upwards

TipRanks05:16 ET

Trump Nominates Marty Makary For FDA Commissioner

Barron'sNov 22 22:27 ET

Why Is Viking Therapeutics (VKTX) Down 29.5% Since Last Earnings Report?

Yahoo FinanceNov 22 11:31 ET

How Is The Market Feeling About Viking Therapeutics?

BenzingaNov 22 11:15 ET

Viking Therapeutics Analyst Ratings

BenzingaNov 22 08:24 ET · Ratings

B.Riley Financial Initiates Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $109

Moomoo NewsNov 21 20:32 ET · Ratings

Viking Therapeutics: Strong Potential in Obesity and Type 2 Diabetes Market With Innovative VK2735 Program

TipRanksNov 21 20:15 ET

Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs

Analyst UpgradesNov 20 13:26 ET

Viking Therapeutics Is More Than Just a Weight-loss Stock, and That's Drawing Cheers

MarketWatchNov 20 12:06 ET

Express News | Viking Therapeutics Shares Rise 4.6% Premarket After Co Presents Detailed Mid-Stage Data for Experimental Liver Disease Drug

ReutersNov 20 05:06 ET

Trending Stocks Today | Tonix Pharmaceuticals Surges 58.63% Post-Market

Moomoo NewsNov 19 18:00 ET

Viking Therapeutics Phase 2b Trial Into Non-Alcoholic Steatohepatitis Meets Primary, Secondary Endpoints

MT NewswiresNov 19 16:51 ET

Express News | Viking Therapeutics Presents Results From Phase 2B Voyage Study of Vk2809 in Biopsy-Confirmed Nash/Mash at the 75TH Liver Meeting® 2024

ReutersNov 19 16:03 ET

Viking Therapeutics Presents Results From Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting 2024

PR NewswireNov 19 16:03 ET

We're Interested To See How Viking Therapeutics (NASDAQ:VKTX) Uses Its Cash Hoard To Grow

Simply Wall StNov 18 08:15 ET

3 Things You Need to Know If You Buy Viking Therapeutics Today

Yahoo FinanceNov 18 04:45 ET

Is It Too Late to Buy Viking Therapeutics Stock?

Yahoo FinanceNov 17 07:05 ET

The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.

Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.

wallstreetcnNov 17 07:00 ET

Express News | Shares of Pharmaceutical and Healthcare Stocks Are Trading Lower. The Sector Has Been Under Pressure After President-elect Trump Nominated Robert F. Kennedy Jr. to Lead the HHS

BenzingaNov 15 15:21 ET

Eli Lilly, Novo Nordisk Shares Slide as Trump Picks RFK Jr. for HHS Post

MarketWatchNov 15 14:25 ET